Hydroxamic acid derivatives of valproic acid exhibit anticonvulsant activity with no teratogenic activity in mouse neural tube defect model. It is effective in the treatment of bipolar disorders.
VAHA (Valproyl hydroxamic acid) is an HDAC inhibitor with less activity than valproic acid against Class I enzymes but much greater Class II activity
Features and Benefits
This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.